122 results on '"Koloski N"'
Search Results
2. The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting
- Author
-
Koloski, N. A., Jones, M., Hammer, J., von Wulffen, M., Shah, A., Hoelz, H., Kutyla, M., Burger, D., Martin, N., Gurusamy, S. R., Talley, N. J., and Holtmann, G.
- Published
- 2017
- Full Text
- View/download PDF
3. Identification of early environmental risk factors for irritable bowel syndrome and dyspepsia
- Author
-
KOLOSKI, N. A., JONES, M., WELTMAN, M., KALANTAR, J., BONE, C., GOWRYSHANKAR, A., WALKER, M. M., and TALLEY, N. J.
- Published
- 2015
- Full Text
- View/download PDF
4. Hen or egg: is there a link between inflammatory bowel and coeliac disease
- Author
-
SHAH, A, TALLEY, N, KOLOSKI, N, BURGER, D, MARTIN, N, WALKER, M, and HOLTMANN, G
- Published
- 2015
5. Case-control analysis of risk factors for poor bowel preparations in outpatient cohorts
- Author
-
KUTYLA, M, HOURIGAN, L, KOLOSKI, N, RICH, G, WHALEY, A, YOUNG, L, TALLEY, N, JOHNSON, B, and HOLTMANN, G
- Published
- 2015
6. What keeps gastroenterologists in the public sector busy? A prospective one month snapshot audit
- Author
-
KHEIR, A, KOLOSKI, N, HOLTMANN, G, WALKER, M, VEYSEY, M, and TALLEY, N
- Published
- 2015
7. Editorial: differentiating chronic idiopathic constipation from constipation-predominant irritable bowel syndrome – possible and important? – Authorsʼ reply
- Author
-
Talley, N. J., Koloski, N. A., and Jones, M. P.
- Published
- 2015
- Full Text
- View/download PDF
8. Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study
- Author
-
Koloski, N. A., Jones, M., Young, M., and Talley, N. J.
- Published
- 2015
- Full Text
- View/download PDF
9. Is geographic variability of incidence and prevalence of Crohnʼs Disease linked to Helicobacter pylori? An ecologic study
- Author
-
SHAH, A, TALLEY, N J, WALKER, M, KOLOSKI, N, SHANAHAN, E R, MORRISON, M, BURGER, D, ANDREWS, J M, MCGUCKIN, M, JONES, M, and HOLTMANN, G
- Published
- 2014
10. Letter: budesonide for functional dyspepsia with duodenal eosinophilia—randomised, double‐blind, placebo‐controlled parallel‐group trial
- Author
-
Talley, N.J., primary, Walker, M.M., additional, Jones, M., additional, Keely, S., additional, Koloski, N., additional, Cameron, R., additional, Fairlie, T., additional, Burns, G., additional, Shah, A., additional, Hansen, T., additional, Harris, G., additional, and Holtmann, G., additional
- Published
- 2021
- Full Text
- View/download PDF
11. Gastroenteritis, overseas travel and antibiotic use and irritable bowel syndrome (IBS) and functional dyspepsia (FD): A population based study
- Author
-
KOLOSKI, N A, JONES, M, WELTMAN, M, KALANTAR, J S, BONE, C, GOWRYSHANKAR, A, and TALLEY, N J
- Published
- 2013
12. Erratum to: The Validity of a New Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for Evaluating Symptoms in the Clinical Setting
- Author
-
Koloski, N. A., Jones, M., Hammer, J., von Wulffen, M., Shah, A., Hoelz, H., Kutyla, M., Burger, D., Martin, N., Gurusamy, S. R., Talley, N. J., and Holtmann, G.
- Published
- 2017
- Full Text
- View/download PDF
13. Commentary: psychological disorders linked to functional dyspepsia
- Author
-
Koloski, N. A., Jones, M., and Talley, N. J.
- Published
- 2012
- Full Text
- View/download PDF
14. The brain–gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study
- Author
-
Koloski, N A, Jones, M, Kalantar, J, Weltman, M, Zaguirre, J, and Talley, N J
- Published
- 2012
- Full Text
- View/download PDF
15. Does the biopsychosocial model explain functional gastrointestinal disorders (FGIDs) over time?
- Author
-
JONES, M, VAN OUDENHOVE, L, KOLOSKI, N, and TALLEY, N J
- Published
- 2011
16. Modifiable risk factors associated with faecal incontinence in older community dwelling women
- Author
-
HALLAND, M, KOLOSKI, N A, JONES, M, BYLES, J, CHIARELLI, P, FORDER, P, and TALLEY, N J
- Published
- 2011
17. Associations between stable psychological characteristics and timing of surgery in inflammatory bowel disease (IBD)
- Author
-
ARGALL, R, KOLOSKI, N A, and RADFORD-SMITH, G
- Published
- 2011
18. Do changes in anxiety and depression levels over time predict the development and exacerbation of functional gastrointestinal disorders (FGIDs) in the general population?
- Author
-
KOLOSKI, N A, JONES, M, KALANTAR, J, WELTMAN, M, ZAGUIRRE, J, and TALLEY, N J
- Published
- 2010
19. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study
- Author
-
Boyce, P. M., Talley, N. J., Burke, C., and Koloski, N. A.
- Published
- 2006
20. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia
- Author
-
KOLOSKI, N. A., TALLEY, N. J., HUSKIC, S. S., and BOYCE, P. M.
- Published
- 2003
21. Letter: evidence of gut-to-brain and brain-to-gut pathways in the pathogenesis of functional gastrointestinal disorders - ‘first-ever’ incidence would be needed to draw conclusions. Authors’ reply
- Author
-
Talley, N. J., primary, Koloski, N. A., additional, and Jones, M. P., additional
- Published
- 2016
- Full Text
- View/download PDF
22. Editorial: challenging established perceptions of brain-gut interactions in functional gastrointestinal disorders - brain-gut, gut-brain, or both? Authors' reply
- Author
-
Talley, N. J., primary, Koloski, N., additional, and Jones, M. P., additional
- Published
- 2016
- Full Text
- View/download PDF
23. Evidence that independent gut-to-brain and brain-to-gut pathways operate in the irritable bowel syndrome and functional dyspepsia: a 1-year population-based prospective study
- Author
-
Koloski, N. A., primary, Jones, M., additional, and Talley, N. J., additional
- Published
- 2016
- Full Text
- View/download PDF
24. Ein validierter Fragebogen verringert den Zeitaufwand für die gastroenterologische Anamnese in der Ambulanz. Validierung und klinischer Einsatz des Fragebogens zum strukturierten Assessment gastrointestinaler Symptome (SAGIS)
- Author
-
Koloski, N, primary, Hammer, J, additional, Wulffen, M von, additional, Hölz, H, additional, Jones, MP, additional, Burger, D, additional, Martin, N, additional, Talley, NJ, additional, and Holtmann, GJ, additional
- Published
- 2016
- Full Text
- View/download PDF
25. Impact of Persistent Constipation on Health-Related Quality of Life and Mortality in Older Community-Dwelling Women
- Author
-
Koloski, N A, primary, Jones, M, additional, Wai, R, additional, Gill, R S, additional, Byles, J, additional, and Talley, Nicholas J, additional
- Published
- 2013
- Full Text
- View/download PDF
26. Performance of the Goldberg Anxiety and Depression Scale in older women
- Author
-
Koloski, N. A., primary, Smith, N., additional, Pachana, N. A., additional, and Dobson, A., additional
- Published
- 2008
- Full Text
- View/download PDF
27. The brainegut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study.
- Author
-
Koloski, N. A., Jones, M., Kalantar, J., Weltman, M., Zaguirre, J., and Talley, N. J.
- Subjects
- *
GASTROINTESTINAL diseases , *ENDOPLASMIC reticulum , *CELLULAR signal transduction , *INFLAMMATORY bowel diseases , *MITOCHONDRIA , *ANXIETY , *MENTAL depression - Abstract
Objective Inflammatory bowel diseases (IBDs) feature multiple cellular stress responses, including endoplasmic reticulum (ER) unfolded protein responses (UPRs). UPRs represent autoregulatory pathways that adjust organelle capacity to cellular demand. A similar mechanism, mitochondrial UPR (mtUPR), has been described for mitochondria. ER UPR in intestinal epithelial cells (IECs) contributes to the development of intestinal inflammation, and since mitochondrial alterations and dysfunction are implicated in the pathogenesis of IBDs, the authors characterised mtUPR in the context of intestinal inflammation. Methods Truncated ornithine transcarbamylase was used to selectively induce mtUPR in a murine IEC line. Dextran sodium sulphate (DSS) was administered to PKR (double-stranded-RNA-activated protein kinase) knockout mice to induce IEC stress in vivo and to test for their susceptibility to DSS-induced colitis. Expression Objective Psychological factors are known to be associated with functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS) and functional dyspepsia (FD). No prospective studies have evaluated whether it is the brain (eg, via anxiety) that drives gut symptoms, or whether gut dysfunction precipitates the central nervous system features such as anxiety. In a 12-year longitudinal, prospective, population-based study, we aimed to determine the directionality of the brainegut mechanism in FGIDs. Design Participants (n=1775) were a random population sample from Australia who responded to a survey on FGIDs in 1997 and agreed to be contacted for future research; 1002 completed the 12-year followup survey (response rate =60%), with 217, 82 and 45 people meeting Rome II for new onset FGIDs, IBS and FD, respectively. Anxiety and depression were measured using the Delusions Symptom States Inventory at baseline and follow-up. Results Among people free of a FGID at baseline, higher levels of anxiety (OR 1.11; 95% CI 1.03 to 1.19, p=0.006) but not depression at baseline was a significant independent predictor of developing new onset FGIDs 12 years later. Among people who did not have elevated levels of anxiety and depression at baseline, those with a FGID at baseline had significantly higher levels of anxiety and depression at follow-up (mean difference coefficient 0.76, p<0.001 and 0.30, p=0.01 for anxiety and depression, respectively). In IBS higher levels of anxiety and depression at baseline were predictive of IBS at follow-up, while only depression was predictive of FD at follow-up. Conclusions The central nervous system and gut interact bidirectionally in FGIDs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. Development and validation of the Geriatric Anxiety Inventory.
- Author
-
Pachana NA, Byrne GJ, Siddle H, Koloski N, Harley E, Arnold E, Pachana, Nancy A, Byrne, Gerard J, Siddle, Helen, Koloski, Natasha, Harley, Emma, and Arnold, Elizabeth
- Abstract
Background: Anxiety symptoms and anxiety disorders are highly prevalent among elderly people, although infrequently the subject of systematic research in this age group. One important limitation is the lack of a widely accepted instrument to measure dimensional anxiety in both normal old people and old people with mental health problems seen in various settings. Accordingly, we developed and tested of a short scale to measure anxiety in older people.Methods: We generated a large number of potential items de novo and by reference to existing anxiety scales, and then reduced the number of items to 60 through consultation with a reference group consisting of psychologists, psychiatrists and normal elderly people. We then tested the psychometric properties of these 60 items in 452 normal old people and 46 patients attending a psychogeriatric service. We were able to reduce the number of items to 20. We chose a 1-week perspective and a dichotomous response scale.Results: Cronbach's alpha for the 20-item Geriatric Anxiety Inventory (GAI) was 0.91 among normal elderly people and 0.93 in the psychogeriatric sample. Concurrent validity with a variety of other measures was demonstrated in both the normal sample and the psychogeriatric sample. Inter-rater and test-retest reliability were found to be excellent. Receiver operating characteristic analysis indicated a cut-point of 10/11 for the detection of DSM-IV Generalized Anxiety Disorder (GAD) in the psychogeriatric sample, with 83% of patients correctly classified with a specificity of 84% and a sensitivity of 75%.Conclusions: The GAI is a new 20-item self-report or nurse-administered scale that measures dimensional anxiety in elderly people. It has sound psychometric properties. Initial clinical testing indicates that it is able to discriminate between those with and without any anxiety disorder and between those with and without DSM-IV GAD. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
29. Is geographic variability of incidence and prevalence of Crohn's Disease linked to Helicobacter pylori? An ecologic study
- Author
-
Shah, A., Talley, N. J., Walker, M., Koloski, N., Erin Shanahan, Morrison, M., Burger, D., Andrews, J. M., Mcguckin, M., Jones, M., and Holtmann, G.
30. Quantitative polymerase chain reaction as a novel approach to determine influence of density of bacterial colonization on health and disease
- Author
-
Shah, A., Erin Shanahan, Berendsen, E., Macdonald, G., Rich, J., Ghasemi, P., Hansen, T., Koloski, N., Burger, D., Keely, S., Walker, M., Talley, N. J., Morrison, M., and Holtmann, G.
31. FUNCTIONAL GASTROINTESTINAL DISORDERS NEGATIVELY IMPACT QUALITY OF LIFE.
- Author
-
Koloski, N. and Talley, N.
- Subjects
- *
GASTROINTESTINAL diseases , *QUALITY of life , *MENTAL health , *PSYCHOLOGY - Abstract
Provides information on a survey regarding gastrointestinal symptoms and the quality of life issues related to functional gastrointestinal disorders (FGID). Impact of FGID on the individual's quality of life; Definition of FGID.
- Published
- 2000
32. A multifaceted ecological approach to explore links between environmental factors and the epidemiology of disorders of gut-brain interaction.
- Author
-
Fairlie T, Shah A, Wong RK, Fang X, Ghoshal UC, Kashyap PC, Mulak A, Lee YY, Sperber AD, Koloski N, Moy N, Talley NJ, Jones MP, and Holtmann G
- Subjects
- Humans, Prevalence, Socioeconomic Factors, Gastrointestinal Diseases epidemiology, Environment, Helicobacter Infections epidemiology, Gross Domestic Product, Brain-Gut Axis physiology
- Abstract
Background: Disorders of gut-brain interaction (DGBI) are characterized by debilitating symptoms not explained by structural or biochemical abnormalities. While functional conditions present with complex, likely heterogeneous pathophysiology, we aimed to investigate if proxy measures of sociocultural and environmental factors are associated with the prevalence of various DGBI in populations across the world., Methods: We performed an ecological study utilizing peer-reviewed published datasets reporting for 26 countries prevalence rates of DGBI (Rome Foundation Global Epidemiology Study, RFGES), with six independent variables: Helicobacter pylori prevalence and household size as proxy measures for orofecal infections, gross domestic product per capita (GDP), and median age as a proxy measures for socioeconomic development, density of fast food outlets (FFO) per 100,000 population as proxy measure for processed food exposure, and suicide mortality rate per 100,000 people, and world happiness scores were used as a proxy for psychological stress. The data were retrieved from publicly accessible datasets (United Nations, CIA World Factbook, World Bank, World Happiness Report, commercial/financial reports of a global FFO chain). We used linear regression to assess variables in univariate and multivariate analysis and report standardized β coefficients with 95% confidence intervals (CI)., Key Results: The regression model revealed that the overall prevalence of DGBI was inversely associated with both GDP per capita (β = -0.57, 95% CI: -0.92, -0.22, p = 0.002) and happiness scores (β = -0.433 95% CI: 0.821, -0.065, p = 0.023), while being positively associated with H. pylori prevalence (β = 0.40, 95% CI: 0.008, 0.81, p = 0.046). The prevalence of functional constipation (FC) was also inversely associated with GDP per capita (β = -0.50, 95% CI: -0.86, -0.13, p = 0.01) and happiness scores (β = -0.497, 95% CI: -0.863, -0.132, p = 0.01), while being positively associated with H. pylori prevalence (β = 0.53, 95% CI: 0.16, 0.91, p = 0.007). The Multivariate model analysis revealed that combining the factors of H. pylori prevalence, suicide rate, household size and happiness scores showed statistically significant association with FC (p = 0.039). Household size (β = -0.43, 95% CI: -0.82, 0.038, p = 0.033) and suicide rates (β = 0.55, 95% CI: 0.19, 0.90, p = 0.004) were statistically significantly associated with functional diarrhea. Irritable bowel syndrome (IBS) was associated with GDP per capita (β = -0.40, 95% CI: -0.79, -0.014, p = 0.043) and happiness scores (β = -0.390, 95% CI: -0.778, -0.003, p = 0.049)., Conclusions & Inferences: Utilizing publicly available data, the prevalence of DGBI across diverse countries is linked to various socio-cultural and environmental factors. Collectively, the data suggests that the prevalence of DGBI is increased in less prosperous regions of the world., (© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
33. The COVID-19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta-analysis.
- Author
-
Kulin D, Shah A, Fairlie T, Wong RK, Fang X, Ghoshal UC, Kashyap PC, Mulak A, Lee YY, Talley NJ, Koloski N, Jones MP, and Holtmann GJ
- Abstract
Background: This SRMA reviewed and assessed the changes in the severity of disorders of gut-brain interaction (DGBI) symptoms during the COVID-19 pandemic, and evaluated factors associated with symptom severity changes., Methods: Electronic databases were searched until February 2024, for articles reporting on changes in symptom severity in DGBI patients during the COVID-19 pandemic. The proportion of DGBI patients who reported a change in their symptom severity were pooled using a random-effects model, and subgroup analyses were conducted to assess the effect of socio-cultural modifiers on symptom severity in DGBI., Key Results: Twelve studies including 3610 DGBI patients found that 31.4% (95% CI, 15.9-52.5) of DGBI patients experienced symptom deterioration, while 24.3% (95% CI, 10.2-47.5) experienced improvement. Countries with high gross domestic product (GDP) had a 43.5% (95% CI, 16.3-75.2) likelihood of symptom deterioration, compared to 9.2% (95% CI, 1.4-42.2) in lower GDP countries. Similarly, countries with low COVID fatality rates had a 60.1% (95% CI, 19.7-90.3) likelihood of symptom deterioration, compared to 18.3% (95% CI, 7.8-36.9) in higher fatality rate countries. Countries with lenient COVID policies had a 58.4% (95% CI, 14.1-92.3) likelihood of symptom deterioration, compared to 19% (95% CI, 8.2-38.1) in countries with stricter policies. Patients in high vaccine hesitancy countries had a 51.4% (95% CI, 19.5-82.2) likelihood of symptom deterioration, compared to 10.6% (95% CI, 2.7-33.4) in low vaccine hesitancy countries., Conclusions & Inferences: This meta-analysis reveals that a significantly higher proportion of DGBI patients experienced deterioration of symptoms during the COVID-19 pandemic. Various sociocultural, economic and environmental factors potentially modify the effects of the COVID-19 pandemic on DGBI., (© 2024 The Author(s). Neurogastroenterology & Motility published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
34. Prevalence of small intestinal bacterial overgrowth in intestinal failure syndrome: A systematic review and meta-analysis.
- Author
-
Shah A, Fairlie T, Morrison M, Martin N, Hammer K, Hammer J, Koloski N, Rezaie A, Pimentel M, Kashyap P, Jones MP, and Holtmann G
- Abstract
Background and Aim: Patients with intestinal failure (IF) have abnormal intestinal anatomy, secretion, and dysmotility, which impairs intestinal homeostatic mechanisms and may lead to small intestinal bacterial overgrowth (SIBO). We conducted a systematic review and meta-analysis to determine the prevalence of SIBO in patients with IF and to identify risk factors for SIBO., Methods: MEDLINE (PubMed) and Embase electronic databases were searched from inception to December 2023 for studies that reported the prevalence of SIBO in IF. The prevalence rates, odds ratio (OR), and 95% confidence intervals of SIBO in IF and the risk factors for SIBO in IF were calculated using random effects model., Results: Final dataset included nine studies reporting on 407 patients with IF. The prevalence of SIBO in IF was 57.5% (95% CI 44.6-69.4), with substantial heterogeneity in this analysis (I
2 = 80.9, P = 0.0001). SIBO prevalence was sixfold higher in patients with IF who received parenteral nutrition (PN) compared with IF patients not on PN (OR = 6.0, 95% CI 3.0-11.9, P = 0.0001). Overall, the prevalence of SIBO in patients with IF using PPI/acid-suppressing agents (72.0%, 95% CI 57.5-83.8) was numerically higher compared with IF patients not using these agents (47.6%, 95% CI 25.7-70.2)., Conclusions: This systematic review and meta-analysis suggests that there is an increased risk of SIBO in patients with IF and that PN, and potentially, the use of PPI/acid-suppressing agents is risk factors for SIBO development in patients with IF. However, the quality of evidence is low and can be attributed to lack of case-control studies and clinical heterogeneity seen in the studies., (© 2024 The Author(s). Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)- Published
- 2024
- Full Text
- View/download PDF
35. Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease.
- Author
-
Koloski N, Shah A, Kaan I, Ben Jacob R, Talley NJ, Jones MP, and Holtmann G
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome therapy, Irritable Bowel Syndrome diagnosis, Gastroesophageal Reflux diagnosis, Gastroesophageal Reflux therapy, Gastroesophageal Reflux epidemiology, Patient Acceptance of Health Care statistics & numerical data, Inflammatory Bowel Diseases therapy, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases diagnosis
- Abstract
Background: Limited information is available about patterns of healthcare utilization for prevalent gastrointestinal conditions and their link to symptom burden., Aim: To identify patterns of healthcare utilization among outpatients with highly prevalent gastrointestinal conditions and define the link between healthcare utilization, symptom burden, and disease group., Methods: We randomly selected patients from the gastroenterology outpatient clinic at Princess Alexandra Hospital who had chronic gastrointestinal conditions such as constipation-predominant irritable bowel syndrome (IBS-C, n = 101), diarrhea-predominant IBS (IBS-D, n = 101), mixed IBS (n = 103), inflammatory bowel disease with acute flare (n = 113), IBD in remission (n = 103), and gastroesophageal reflux disease (n = 102). All had presented at least 12 months before and had a 12-month follow-up after the index consultation. Healthcare utilization data were obtained from state-wide electronic medical records over a 24-month period. Intensity of gastrointestinal symptoms was measured using the validated Structured Assessment of Gastrointestinal Symptoms (SAGIS) Scale. Latent class analyses (LCA) based on healthcare utilization were used to identify distinct patterns of healthcare utilization among these patients., Results: LCA revealed four distinct healthcare utilization patterns across all diagnostic groups: Group A: Emergency department utilizers, Group B: Outpatient focused care utilizers, Group C: Inpatient care utilizers and Group D: Inpatient care and emergency department utilizers. LCA groups with high emergency utilization were characterized by high gastrointestinal symptom burden at index consultation regardless of condition (Mean (standard deviation)) SAGIS score Group A: 24.63 (± 14.11), Group B: 19.18 (± 15.77), Group C: 22.48 (± 17.42), and Group D: 17.59 (± 13.74, p < 0.05)., Conclusion: Distinct healthcare utilization patterns across highly prevalent gastrointestinal conditions exist. Symptom severity rather than diagnosis, likely reflecting unmet clinical need, defines healthcare utilization., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. What impact has the Centre of Research Excellence in Digestive Health made in the field of gastrointestinal health in Australia and internationally? Study protocol for impact evaluation using the FAIT framework.
- Author
-
Koloski N, Duncanson K, Ramanathan SA, Rao M, Holtmann G, and Talley NJ
- Subjects
- Humans, Australia, New England, Translational Research, Biomedical, Research Design
- Abstract
Introduction: The need for public research funding to be more accountable and demonstrate impact beyond typical academic outputs is increasing. This is particularly challenging and the science behind this form of research is in its infancy when applied to collaborative research funding such as that provided by the Australian National Health and Medical Research Council to the Centre for Research Excellence in Digestive Health (CRE-DH)., Methods and Analysis: In this paper, we describe the protocol for applying the Framework to Assess the Impact from Translational health research to the CRE-DH. The study design involves a five-stage sequential mixed-method approach. In phase I, we developed an impact programme logic model to map the pathway to impact and establish key domains of benefit such as knowledge advancement, capacity building, clinical implementation, policy and legislation, community and economic impacts. In phase 2, we have identified and selected appropriate, measurable and timely impact indicators for each of these domains and established a data plan to capture the necessary data. Phase 3 will develop a model for cost-consequence analysis and identification of relevant data for microcosting and valuation of consequences. In phase 4, we will determine selected case studies to include in the narrative whereas phase 5 involves collation, data analysis and completion of the reporting of impact.We expect this impact evaluation to comprehensively describe the contribution of the CRE-DH for intentional activity over the CRE-DH lifespan and beyond to improve outcomes for people suffering with chronic and debilitating digestive disorders., Ethics and Dissemination: This impact evaluation study has been registered with the Hunter New England Human Research Ethics Committee as project 2024/PID00336 and ethics application 2024/ETH00290. Results of this study will be disseminated via medical conferences, peer-reviewed publications, policy submissions, direct communication with relevant stakeholders, media and social media channels such as X (formely Twitter)., Competing Interests: Competing interests: NK, KD, SAR and MR disclose no conflicts. NT is Emeritus Editor-in-Chief of Medical Journal of Australia, Section Editor of Up to Date and has research collaborations with Intrinsic Medicine (human milk oligosaccharide), Alimentry (gastric mapping) and is a consultant for Agency for Health Care Research and Quality (fiber and laxation), outside the submitted work. In addition, he has licenced Nepean Dyspepsia Index (NDI) to MAPI, and Talley Bowel Disease Questionnaire licensed to Mayo/Talley, 'Diagnostic marker for functional gastrointestinal disorders' Australian Provisional Patent Application 2021901692, 'Methods and compositions for treating age-related neurodegenerative disease associated with dysbiosis' US Patent Application No. 63/537,725. GH received unrestricted educational support from the Falk Foundation. Research support was provided via the Princess Alexandra Hospital, Brisbane by GI Therapies, Takeda Development Center Asia, Eli Lilly Australia, F. Hoffmann-La Roche, MedImmune, Celgene, Celgene International II Sarl, Gilead Sciences, Quintiles, Vital Food Processors, Datapharm Australia Commonwealth Laboratories, Prometheus Laboratories, FALK GmbH & Co KG, Nestle, Mylan and Allergan (prior to acquisition by AbbVie). GH is also a patent holder for a biopsy device to take aseptic biopsies (US 20150320407 A1)., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
37. Social determinants and participation in fecal occult blood test based colorectal cancer screening: A qualitative systematic review and meta-synthesis.
- Author
-
Marinucci N, Moy N, Koloski N, Shah A, Austin G, Russell-Bennett R, McGraw J, Dulleck U, and Holtmann G
- Subjects
- Humans, Early Detection of Cancer methods, Mass Screening, Research Design, Social Determinants of Health, Qualitative Research, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms prevention & control, Occult Blood
- Abstract
Issue Addressed: Colorectal cancer (CRC) screening through fecal occult blood testing (FOBT) has saved thousands of lives globally with multiple countries adopting comprehensive population wide screening programs. Participation rates in FOBT based CRC screening for the socially and economically disadvantaged remains low. The aim of this systematic review is to explore empirical evidence that will guide targeted interventions to improve participation rates within priority populations., Methods: PubMed, Embase, Scopus, Cinahl and PsycInfo were systematically searched from inception to 22 June 2022. Eligible studies contained qualitative evidence identifying barriers to FOBT based CRC screening for populations impacted by the social determinants of health. An inductive thematic synthesis approach was applied using grounded theory methodology, to explore descriptive themes and interpret these into higher order analytical constructs and theories., Results: A total of 8,501 publications were identified and screened. A total of 48 studies from 10 countries were eligible for inclusion, representing 2,232 subjects. Coding within included studies resulted in 30 key descriptive themes with a thematic frequency greater than 10%. Coded themes applied to four overarching, interconnected barriers driving inequality for priority populations: social, behavioural, economic and technical/interfaces. SO WHAT?: This study has highlighted the need for stronger patient/provider relationships to mitigate barriers to FOBT screening participation for diverse groups. Findings can assist health professionals and policy makers address the systemic exclusion of priority populations in cancer screening by moving beyond the responsibility of the individual to a focus on addressing the information asymmetry driving low value perceptions., (© 2023 The Authors. Health Promotion Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of Australian Health Promotion Association.)
- Published
- 2024
- Full Text
- View/download PDF
38. TRAV26-2 T-Cell Receptor Expression Is Associated With Mucosal Lymphocyte Response to Wheat Proteins in Patients With Functional Dyspepsia.
- Author
-
Burns GL, Potter M, Mathe A, Bruce J, Minahan K, Barnes JL, Pryor J, Nieva C, Sherwin S, Cuskelly A, Fairlie T, Cameron R, Bollipo S, Irani MZ, Foster R, Gan LT, Shah A, Koloski N, Foster PS, Horvat JC, Walker MM, Powell N, Veysey M, Duncanson K, Holtmann G, Talley NJ, and Keely S
- Subjects
- Humans, Gliadin metabolism, Triticum genetics, Lymphocytes metabolism, Lymphocytes pathology, Glutens, Intestinal Mucosa pathology, Receptors, Antigen, T-Cell metabolism, Dyspepsia etiology
- Abstract
Introduction: An association between functional dyspepsia (FD) and wheat-containing foods has been reported in observational studies; however, an adaptive response has not been demonstrated. We examined whether antigens present in wheat could provoke a response from FD duodenal lymphocytes., Methods: Lamina propria mononuclear cells (LPMCs) were isolated from duodenal biopsies from 50 patients with FD and 23 controls. LPMCs were exposed to gluten (0.2 mg/mL) or gliadin (0.2 mg/mL) for 24 hours. Flow cytometry was performed to phenotype lymphocytes. Quantitative PCR was used to measure the expression of gliadin-associated T-cell receptor alpha variant ( TRAV ) 26-2., Results: In response to gliadin (but not gluten) stimulation, the effector Th2-like population was increased in FD LPMCs compared with that in controls and unstimulated FD LPMCs. Duodenal gene expression of TRAV26- 2 was decreased in patients with FD compared with that in controls. We identified a positive association between gene expression of this T-cell receptor variant and LPMC effector Th17-like cell populations in patients with FD, but not controls after exposure to gluten, but not gliadin., Discussion: Our findings suggest that gliadin exposure provokes a duodenal effector Th2-like response in patients with FD, supporting the notion that food antigens drive responses in some patients. Furthermore, these findings suggest that altered lymphocyte responses to wheat proteins play a role in FD pathogenesis., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
- Published
- 2023
- Full Text
- View/download PDF
39. Overlap of disorders of gut-brain interaction: a systematic review and meta-analysis.
- Author
-
Fairlie T, Shah A, Talley NJ, Chey WD, Koloski N, Yeh Lee Y, Gwee KA, Jones MP, and Holtmann G
- Subjects
- Adult, Humans, Adolescent, Cross-Sectional Studies, Comorbidity, Brain, Observational Studies as Topic, Quality of Life, Anxiety epidemiology
- Abstract
Background: Rome criteria differentiate distinct types of disorders of gut-brain interaction (DGBI); also known as functional gastrointestinal disorders. Overlap of symptom categories frequently occurs. This systematic review and meta-analysis aimed to define the prevalence of DGBI overlap and compare overlap in population-based, primary care or tertiary care health settings. Furthermore, we aimed to compare symptom severity of psychological comorbidities in DGBI with and without overlap., Methods: For this systematic review and meta-analysis we searched MEDLINE (PubMed) and Embase electronic databases from inception until March 1, 2022, for original articles and conference abstracts of observational cross-sectional, case-controlled, or cohort design studies that reported the prevalence of DGBI overlap in adult participants (aged ≥18 years). We included only those studies where the diagnosis of DGBI was based on clinical assessment, questionnaire data, or specific symptom-based criteria. Studies were excluded if reporting on mixed populations of DGBI and organic diseases. Aggregate patient data were extracted from eligible published studies. The prevalence of DGBI overlap in all studies was pooled using the DerSimonian and Laird random effects model, and further analysis stratified by subgroups (care setting, diagnostic criteria, geographic region, and gross domestic product per capita). We also assessed the relationship between DGBI overlap with anxiety, depression, and quality of life symptom scores. This study was registered with PROSPERO (CRD42022311101)., Findings: 46 of 1268 screened studies, reporting on 75 682 adult DGBI participants, were eligible for inclusion in this systematic review and meta-analysis. Overall, 24 424 (pooled prevalence 36·5% [95% CI 30·7 to 42·6]) participants had a DGBI overlap, with considerable between-study heterogeneity (I
2 =99·51, p=0·0001). In the tertiary health-care setting, overlap among participants with DGBI was more prevalent (8373 of 22 617, pooled prevalence 47·3% [95% CI 33·2 to 61·7]) compared with population-based cohorts (11 332 of 39 749, pooled prevalence 26·5% [95% CI 20·5 to 33·4]; odds ratio 2·50 [95% CI 1·28 to 4·87]; p=0·0084). Quality of life physical component scores were significantly lower in participants with DGBI overlap compared with participants without overlap (standardised mean difference -0·47 [95% CI -0·80 to -0·14]; p=0·025). Participants with DGBI overlap had both increased symptom scores for anxiety (0·39 [95% CI 0·24 to 0·54]; p=0·0001) and depression (0·41 [0·30 to 0·51]; p=0·0001)., Interpretation: Overlap of DGBI subtypes is frequent, and is more prevalent in tertiary care settings and associated with more severe symptom manifestations or psychological comorbidities. Despite the large sample size, the comparative analyses revealed substantial heterogeneity, and the results should be interpreted with caution., Funding: National Health and Medical Research Council and Centre for Research Excellence., Competing Interests: Declaration of interests GH has received payments or honoraria for lectures, presentations, or speakers bureaus from Bayer, and has also received travel/support for attending meetings from Bayer. He has participated on data safety monitoring boards or advisory boards from Australian Biotherapeutics, Glutagen, and Bayer. GH holds stock or stock options in Bayer. He serves on the boards of the West Moreton Hospital and Health Service (WMHHS), Queensland, UQ Healthcare, Brisbane, and is vice president of Gastro-Liga, Germany, and Chair of the WMHHS Board Quality and Safety Committee. He is on the Research Committee of the Royal Australasian College of Physicians. GH acknowledges funding from the National Health and Medical Research Council (NHMRC) for the Centre for Research Excellence in Digestive Health. GH holds a Medical Research Future Fund grant and an NHMRC ideas grant. NJT reports grants from NHMRC (Centre for Research Excellence in Digestive Health; investigator grant), HMRI, Defence department of the Australian government (Cognobiome grant), AusEE, Astra Zeneca, Allakos, and Intrinsic Medicine. He reports personal fees from Adelphi values, Allakos, Astra Zeneca, Bayer AG, Comvita Mānuka Honey, BluMaiden, twoXAR, Dr Falk Pharma/Jorveza, Glutagen, IsoThrive, Intrinsic Medicine, and Rose Pharma, and has acted as an educational speaker for GlaxoSmithKline Australia. He has non-financial support from Norgine for an IBS interest group. NJT has a patent for biomarkers of IBS licensed (#12735358·9 -1405/2710383 and #12735358·9 -1405/2710384), has licensed questionnaires (Talley Bowel Disease Questionnaire) to the Mayo Clinic, has a Nestec European Patent Application (No. 12735358·9), has a provision Australian patent application for a diagnostic marker for functional gastrointestinal disorders (2021901692), a Singapore provisional patent (NTU Ref: TD/129/17 “Microbiota Modulation Of BDNF Tissue Repair Pathway”), and copyright Nepean Dyspepsia Index (NDI) 1998. He has acted on an advisory board for Bristol Myers Squibb. NJT declares the following other financial or non-financial interests: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea (Editorial Board Member), Med (Journal of Cell Press; Editorial Board Member), eGastroenterology (Editorial Board Member), and has received personal fees for a textbook from Elsevier. NJT has leadership or fiduciary roles (all unpaid) in the International Foundation for Functional Gastrointestinal Disorders (IFFGD; advisory board), AusEE (advisory board), OzSage, NHMRC Principal Committee (Research Committee), Asia Pacific Association of Medical Journal Editors (APAME), AAHMS, Rome V working team member (gastroduodenal committee), International Plausibility Project Co-Chair (Rome Foundation funded), COVID-19 vaccine forum member. WDC reports grants from Biomerica, Commonwealth Diagnostics International, QOL Medical, and Salix/Valeant, has received consulting fees from AbbVie, Alnylam, Biomerica, Gemelli, Ironwood, Isothrive, QOL Medical, Nestle, Redhill, Salix/Valenat, Urovant, Takeda, and Vibrant. He is on the board of trustees and an officer of the American College of Gastroenterology, board of directors of the Rome Foundation, and board of directors and is vice president of the IFFGD. TF, AS, NK, YYL, KAG, and MPG declare no competing interests., (Copyright © 2023 Elsevier Ltd. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
40. Upper GI endoscopy in subjects with positive fecal occult blood test undergoing colonoscopy: systematic review and meta-analysis.
- Author
-
Shah A, Eqbal A, Moy N, Koloski N, Messmann H, Kendall BJ, Sharma P, Dulleck U, Jones MP, and Holtmann GJ
- Subjects
- Humans, Occult Blood, Prospective Studies, Colonoscopy, Endoscopy, Gastrointestinal, Mass Screening, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms complications, Anemia epidemiology
- Abstract
Background and Aims: The role of gastroscopy to investigate the upper GI (UGI) tract in subjects with a positive fecal occult blood test (FOBT+) result is controversial. We conducted a systematic review and meta-analysis, which aimed to determine the prevalence of UGI lesions in FOBT+ subjects., Methods: Databases were searched until March 31, 2022 for studies reporting UGI lesions in FOBT+ subjects undergoing colonoscopy and gastroscopy. Pooled prevalence rates of UGI cancers and clinically significant lesions (CSLs; lesions potentially explaining occult blood loss), odds ratio (OR), and 95% confidence intervals (CIs) were calculated., Results: We included 21 studies with 6993 FOBT+ subjects. Pooled prevalence of UGI cancers was .8% (95% CI, .4-1.6) and UGI CSLs was 30.4% (95% CI, 20.7-42.2), and that of colonic cancers and CSLs was 3.3% (95% CI, 1.8-6.0) and 31.9% (95% CI, 23.9-41.1), respectively. There was no significant difference in the prevalence of UGI CSL and UGI cancers in FOBT+ subjects with/without colonic pathology (ORs of 1.2 [95% CI, .9-1.6; P = .137] and 1.6 [95% CI, .5-5.5; P = .460]). Anemia in FOBT+ subjects was associated with UGI cancers (OR, 6.3; 95% CI, 1.3-31.5; P = .025) and UGI CSLs (OR, 4.3; 95% CI, 2.2-8.4; P = .0001). GI symptoms were not associated with UGI CSLs (OR, 1.3; 95% CI, .6-2.8; P = .511)., Conclusions: There is an appreciable prevalence of UGI cancers and other CSLs in FOBT+ subjects. Anemia but not symptoms or colonic pathology are linked to UGI lesions. Although the data suggest that same-day gastroscopy in FOBT+ subjects undergoing colonoscopy yields approximately 25% more malignancies as colonoscopy alone, prospective data are required to determine the cost-efficacy of dual endoscopy as a standard of care for all FOBT+ subjects., (Copyright © 2023 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Development and Validation of a Patient-Reported Experience Measure for Gastrointestinal Endoscopy: The Comprehensive Endoscopy Satisfaction Tool (CEST).
- Author
-
Kutyla MJ, McMaster JJ, Haig A, Koloski N, Hourigan L, Meeusen V, Shah A, Talley NJ, Jones MP, and Holtmann GJ
- Subjects
- Humans, Patient Reported Outcome Measures, Surveys and Questionnaires, Endoscopy, Gastrointestinal methods, Patient Satisfaction
- Abstract
Goals: We aimed to develop and validate a patient-reported experience measure for gastrointestinal (GI) endoscopy, the Comprehensive Endoscopy Satisfaction Tool that captures relevant domains that influence the patient's experience and identify factors that shape satisfaction., Background: Patient-reported experience measures are used to capture specific quality aspects of health care services. GI endoscopic services are high-volume services, and there is a lack of specific, validated instruments to capture various domains that shape the patients' experience with routine clinical endoscopic services., Study: After an environmental scan and structured literature review, focus groups with patients were conducted to identify relevant factors influencing the patient experience with GI endoscopic services. After an initial validation in 101 patients undergoing routine GI endoscopies, the instrument was tested in 7800 patients. In addition, the influence of sociodemographic factors on global satisfaction was explored., Results: The final version included 26 specific items plus 4 global ratings for preprocedure, experience on day of procedure, postprocedure care, and infrastructure. In addition, a global rating of the overall experience was included. Patient satisfaction was significantly higher in older patients (P<0.001) but not influenced by gender, nationality, marital status, education, or employment status. Interestingly, during periods of coronavirus disease-19-related service interruptions, the Net Promoter Score was significantly reduced (P<0.0001) providing evidence for the responsiveness of the instrument., Conclusions: The Comprehensive Endoscopy Satisfaction Tool is a valid measure for the patient experience with the various components of endoscopic services, allows for the identification of domains that impact on the patient experience and is a practical tool to compare patient satisfaction over time and across facilities., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
42. How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?
- Author
-
Shah A, Pakneeshan S, Jones MP, Koloski N, Callaghan G, Morrison M, and Holtmann G
- Subjects
- Female, Humans, Young Adult, Adult, Middle Aged, Vancomycin therapeutic use, Retrospective Studies, Prospective Studies, Cohort Studies, Anti-Bacterial Agents therapeutic use, Colitis, Ulcerative drug therapy, Colitis, Ulcerative complications, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing drug therapy, Vancomycin-Resistant Enterococci
- Abstract
In patients with primary sclerosing cholangitis (PSC), antimicrobial therapy with oral vancomycin (OV) is increasingly used to prevent progression of the liver disease and control concomitant ulcerative colitis (UC); however, there are concerns regarding the risk of development of vancomycin-resistant enterococci (VRE). Thus, we aimed to determine the incidence of VRE in PSC-UC patients. We conducted a retrospective study of PSC-UC patients, treated with OV at the Department of Gastroenterology at the Princess Alexandra Hospital. VRE testing was performed utilizing rectal swabs. We included 7 PSC-UC patients (age 22-53 years, 2 females) treated with OV with daily dose ranging from 250 to 1500 mg. All patients were treated for at least 6 months with OV (range 9-31 months, mean 32.1 months). All patients achieved complete clinical remission of the UC, with mean reduction of fecal calprotectin by 634 μg/mg (87.3%), mean reduction in the C-reactive protein by 21.9 mg/L (74.2%), and mean reduction in the total Mayo score by 9.3 (93.3%). With regard to the liver parameters, mean improvement in alkaline phosphatase enzyme and total bilirubin was -48.7 U/L (-19.7%) and -2.7 mg/dL (-19.6%), respectively. No patient treated with OV developed VRE or reported any adverse events. This cohort study including PSC-UC patients did not provide evidence for development of VRE, while treatment with vancomycin was associated with clinical and endoscopic remission of the UC. Larger, prospective trials are required to define the efficacy and safety of antimicrobial therapy in PSC-UC, while the risk of VRE appears small., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
43. Duodenal Eosinophils and Mast Cells in Functional Dyspepsia: A Systematic Review and Meta-Analysis of Case-Control Studies.
- Author
-
Shah A, Fairlie T, Brown G, Jones MP, Eslick GD, Duncanson K, Thapar N, Keely S, Koloski N, Shahi M, Walker MM, Talley NJ, and Holtmann G
- Subjects
- Case-Control Studies, Duodenum, Eosinophils, Humans, Mast Cells, Dyspepsia, Eosinophilia
- Abstract
Background & Aims: This study explored the link between duodenal eosinophils and mast cells in patients with functional dyspepsia (FD)., Methods: MEDLINE (PubMed) and Embase electronic databases were searched until June 2021 for case-control studies reporting duodenal eosinophils and mast cells in FD. Pooled standardized mean difference (SMD), odds ratio, and 95% CIs of duodenal eosinophils and mast cells in FD patients and controls were calculated, using a random-effects model., Results: Twenty-two case-control studies with 1108 FD patients and 893 controls were identified. Duodenal eosinophils (SMD, 1.29; 95% CI, 0.85-1.73; P = .0001) and mast cells (SMD, 2.11; 95% CI, 1.14-3.07; P = .0001) were increased in FD patients compared with controls. Substantial heterogeneity was found (I
2 = 93.61, P = .0001; and I2 = 96.69, P = .0001, respectively) and visual inspection of funnel plots confirmed publication bias. Degranulation of duodenal eosinophils was significantly higher in FD patients compared with controls (odds ratio, 3.78; 95% CI, 6.76-4.48; P = .0001), without statistically significant heterogeneity. We conducted a sensitivity analysis for duodenal eosinophils, by including only high-quality studies, and the results remained unchanged (SMD, 1.73; 95% CI, 1.06-2.40; P = .0001), with substantial heterogeneity. Postinfectious FD patients had increased duodenal eosinophils compared with controls (SMD, 3.91; 95% CI, 1.32-6.51; P = .001) and FD patients without any history of infection (SMD, 1.42; 95% CI, 0.88-1.96; P = .001). Helicobacter pylori-negative FD patients had significantly higher duodenal eosinophils compared with controls (SMD, 3.98; 95% CI, 2.13-5.84; P = .0001), with substantial heterogeneity. No significant difference in duodenal eosinophils was seen according to FD subtypes., Conclusions: This meta-analysis suggests a link between duodenal microinflammation and FD. However, the quality of evidence is very low, largely owing to the unexplained heterogeneity and serious risk of publication bias in all comparative analyses. Thus, causality remains uncertain and further studies are required., (Copyright © 2022. Published by Elsevier Inc.)- Published
- 2022
- Full Text
- View/download PDF
44. Utilising lipid and, arginine and proline metabolism in blood plasma to differentiate the biochemical expression in functional dyspepsia (FD) and irritable bowel syndrome (IBS).
- Author
-
Karpe AV, Liu JW, Shah A, Koloski N, Holtmann G, and Beale DJ
- Subjects
- Arginine, Humans, Lipids, Metabolomics, Plasma, Proline, Dyspepsia diagnosis, Dyspepsia etiology, Gastrointestinal Diseases complications, Gastrointestinal Diseases diagnosis, Irritable Bowel Syndrome diagnosis
- Abstract
Functional gastrointestinal disorders (FGID) such as functional dyspepsia (FD) and irritable bowel syndrome (IBS) are highly prevalent and debilitating attributed to altered gut function and gut-brain interactions. FGID can be reliably diagnosed based upon the symptom pattern; but in the clinical setting FD or IBS a frequent diagnoses of exclusion after relevant structural causes of symptoms have been ruled out by appropriate testing. Thus far, there is no established biomarker for FGIDs. To address this limitation, we utilised multi-omics and chemometrics integration to characterise the blood plasma biochemistry in patients with IBS, FD, an overlap of FD/IBS, and controls using liquid chromatography-mass spectrometry (LC-MS) techniques.Cholesterol metabolism products Cholest-5,24-dien-3β-ol, 3-O-β-D-glucopyranoside, energy pathway metabolites, immunoglobulin-γ2 and immunoglobulin-κ, and carbonic anhydrase-1 proteins were particularly elevated in IBS. Furthermore, arginine and proline metabolisms, thyroid hormone synthesis, ferroptosis and, complementary and coagulation cascades were particularly upregulated in patients with IBS. Cer(d18:1/26:1(17Z)) and PI(14:0/22:1(11Z)) lipids were elevated in FD and FD-IBS but were depleted in IBS. Markers of central carbon metabolism and lipidome profiles allowed better discrimination and model predictability than metaproteome profile in healthy and FGID conditions.Overall, the multi-omics integration allowed the discrimination of healthy controls and FGID patients. It also effectively differentiated the biochemistry of FGID subtypes including FD, IBS and FD-IBS co-occurrence. This study points towards the possibility of multi-omics integration for rapid and high throughput analysis of plasma samples to support clinicians screen and diagnose patients with suspected FGIDs., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
45. Concomitant Irritable Bowel Syndrome Does Not Influence the Response to Antimicrobial Therapy in Patients with Functional Dyspepsia.
- Author
-
Shah A, Gurusamy SR, Hansen T, Callaghan G, Talley NJ, Koloski N, Walker MM, Jones MP, Morrison M, and Holtmann GJ
- Subjects
- Adult, Anti-Bacterial Agents therapeutic use, Diarrhea, Humans, Rifaximin therapeutic use, Anti-Infective Agents, Dyspepsia diagnosis, Dyspepsia drug therapy, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome diagnosis, Irritable Bowel Syndrome drug therapy
- Abstract
Background and Aims: Antimicrobial therapy improves symptoms in patients with irritable bowel syndrome (IBS), but the efficacy in functional dyspepsia (FD) is largely unknown. While FD and IBS frequently overlap, it is unknown if concomitant IBS in FD alters the response to antimicrobial therapy in FD. Thus, we aimed to assess and compare the effect of antimicrobial therapy on visceral sensory function and symptom improvement in FD patients with and without IBS., Methods: Adult patients with FD with or without IBS received rifaximin 550 mg BD for 10 days, followed by a 6-week follow-up period. The total gastrointestinal symptom score as measured by the SAGIS (Structured Assessment of Gastrointestinal Symptoms) questionnaire and subscores (dyspepsia, diarrhea, and constipation), symptom response to a standardized nutrient challenge and normalization of the glucose breath tests were measured., Results: Twenty-one consecutive adult patients with FD and 14/21 with concomitant IBS were recruited. Treatment with rifaximin resulted in a significant (p = 0.017) improvement in the total SAGIS score from 34.7 (± 15.4) at baseline to 26.0 (± 16.8) at 2 weeks and 25.6 (± 17.8) at 6 weeks post-treatment. Similarly, compared to baseline there was a statistically significant improvement in SAGIS subscores for dyspepsia and diarrhea (all p < 0.05) and effects persisted for 6 weeks post-treatment. Similarly, the symptom score (and subscores) following a standardized nutrient challenge improved significantly (p < 0.001) 2 weeks post-treatment. The presence of concomitant IBS did not significantly influence the improvement of symptoms after antibiotic therapy (all p > 0.5)., Conclusions: In FD patients, the response to antimicrobial therapy with rifaximin is not influenced by concomitant IBS symptoms., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
46. Defects in NLRP6, autophagy and goblet cell homeostasis are associated with reduced duodenal CRH receptor 2 expression in patients with functional dyspepsia.
- Author
-
Bruce JK, Burns GL, Sinn Soh W, Nair PM, Sherwin S, Fan K, Dowling LR, Goggins BJ, Koloski N, Potter M, Bollipo S, Foster R, Gan LT, Veysey M, Philpott DJ, Girardin SE, Holtmann G, Kaiko GE, Walker MM, Talley NJ, and Keely S
- Subjects
- Autophagy, Duodenum metabolism, Goblet Cells metabolism, Homeostasis, Hormones metabolism, Humans, Hypothalamo-Hypophyseal System metabolism, Dyspepsia metabolism, Intracellular Signaling Peptides and Proteins genetics, Pituitary-Adrenal System metabolism, Receptors, Corticotropin-Releasing Hormone genetics, Receptors, Corticotropin-Releasing Hormone metabolism
- Abstract
Functional dyspepsia (FD) affects up to 15% of the population and is characterised by recurring upper gastrointestinal (GI) symptoms occurring in the absence of clinically identifiable pathology. Psychological stress is a key factor associated with the onset of FD and locally acting hypothalamic-pituitary-adrenal (HPA) axis hormones have been implicated in GI motility and barrier dysfunction. Recent pre-clinical work has identified mechanistic pathways linking corticotropin-releasing hormone (CRH) with the innate epithelial immune protein NLRP6, an inflammasome that has been shown to regulate GI mucus secretion. We recruited twelve FD patients and twelve healthy individuals to examine whether dysregulation of hypothalamic-pituitary adrenal (HPA) axis hormones and altered NLRP6 pathways were evident in the duodenal mucosa. Protein expression was assessed by immunoblot and immunohistochemistry in D2 duodenal biopsies. Plasma HPA axis hormones were assayed by ELISA and enteroid and colorectal cancer cell line cultures were used to verify function. FD patients exhibited reduced duodenal CRH-receptor 2, compared to non-GI disease controls, indicating a dysregulation of duodenal HPA signalling. The loss of CRH-receptor 2 correlated with reduced NLRP6 expression and autophagy function, processes critical for maintaining goblet cell homeostasis. In accordance, duodenal goblet cell numbers and mucin exocytosis was reduced in FD patients compared to controls. In vitro studies demonstrated that CRH could reduce NLRP6 in duodenal spheroids and promote mucus secretion in the HT29-MTX-E12 cell line. In conclusion, FD patients exhibit defects in the NLRP6-autophagy axis with decreased goblet cell function that may drive symptoms of disease. These features correlated with loss of CRH receptor 2 and may be driven by dysregulation of HPA signalling in the duodenum of FD patients., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
47. Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis.
- Author
-
Gurusamy SR, Shah A, Talley NJ, Koloski N, Jones MP, Walker MM, Morrison M, and Holtmann G
- Subjects
- Bacterial Infections epidemiology, Bacterial Load, Breath Tests, Dyspepsia epidemiology, Humans, Prevalence, Bacterial Infections microbiology, Dyspepsia microbiology, Intestine, Small microbiology
- Abstract
Introduction: This systematic review and meta-analysis aimed to determine the role of small intestinal bacterial overgrowth (SIBO) in patients with functional dyspepsia (FD)., Methods: Electronic databases were searched until July 2020 for studies reporting prevalence of SIBO in FD. The prevalence rates, odds ratio, and 95% confidence intervals (CIs) of SIBO in FD and controls were calculated., Results: Seven studies with 263 patients with FD and 84 controls were identified. The odds for SIBO in patients with FD were significantly higher as compared to that in controls (odds ratio = 4.3, 95% CI, 1.1-17.5, 4 studies, 234 participants); however, there was moderate heterogeneity in this analysis. Including high-quality, case-control studies (all using glucose breath tests [GBTs]), the risk of SIBO in patients with FD as compared to controls was 2.8 higher (95% CI 0.8-10.0, 3 studies, 200 participants) with minimal heterogeneity in this analysis. Using the lactulose breath test, SIBO prevalence in FD was significantly higher (53.4%, 95% CI 33.9-71.9, 3 studies, 110 participants) as compared to that with GBT (17.2%, 95% CI 8.6-31.6, 4 studies, 153 participants). Substantial heterogeneity was found in studies using the lactulose breath test but not in studies using GBT. There was no significant difference in SIBO prevalence in patients with FD according to FD subtype., Discussion: This meta-analysis suggests a link between FD and SIBO. The quality of evidence is low and can be largely attributed to the type of breath test for SIBO diagnosis and clinical heterogeneity. More appropriately designed studies are required to confirm the link between SIBO and FD., (Copyright © 2021 by The American College of Gastroenterology.)
- Published
- 2021
- Full Text
- View/download PDF
48. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis.
- Author
-
Gandhi A, Shah A, Jones MP, Koloski N, Talley NJ, Morrison M, and Holtmann G
- Subjects
- Bacteria genetics, Bacteria isolation & purification, Bacteria metabolism, Breath Tests, Case-Control Studies, Female, Humans, Male, Methane analysis, Bacteria growth & development, Inflammatory Bowel Diseases microbiology, Intestine, Small microbiology, Irritable Bowel Syndrome microbiology, Methane metabolism
- Abstract
Several studies reported a potential role of methane producing archaea in the pathophysiology of irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the prevalence of methane positive small intestinal bacterial overgrowth (SIBO) in IBS and IBD compared with controls. MEDLINE (PubMed) and Embase electronic databases were searched from inception until March 2021 for case-control and prevalence studies reporting SIBO in IBS and IBD. We extracted data from published studies and calculated pooled prevalence of SIBO in IBS or IBD, odds ratios (OR), and 95% CIs, utilizing a random effects model. The final dataset included 17 independent studies assessing the prevalence of methane positive SIBO in 1,653 IBS-patients and 713 controls, and 7 studies assessing the prevalence of methane positive SIBO in 626 IBD-patients and 497 controls, all utilizing breath test for SIBO diagnosis. Prevalence of methane positive SIBO in IBS and IBD was 25.0% (95% CI 18.8-32.4) and 5.6% (95% CI 2.6-11.8), respectively. Methane positive SIBO in IBS was not increased compared to controls (OR = 1.2, 95% CI 0.8-1.7, P = .37) but was significantly more prevalent in IBS-C as compared to IBS-D (OR = 3.1, 95% CI 1.7-5.6, P = .0001). The prevalence of methane-positive SIBO in patients with IBD was 3-fold lower at 7.4% (95% CI 5.4-9.8) compared to 23.5% (95% CI 19.8-27.5) in controls. The prevalence of methane positive SIBO was significantly lower in Crohn's disease as compared to ulcerative colitis, (5.3%, 95% CI 3.0-8.5 vs. 20.2%, 95% CI 12.8-29.4). This systematic review and meta-analysis suggests methane positivity on breath testing is positively associated with IBS-C and inversely with IBD. However, the quality of evidence is low largely due to clinical heterogeneity of the studies. Thus, causality is uncertain and further studies are required.
- Published
- 2021
- Full Text
- View/download PDF
49. Is there a causal link between psychological disorders and functional gastrointestinal disorders?
- Author
-
Koloski N, Holtmann G, and Talley NJ
- Subjects
- Anxiety diagnosis, Anxiety epidemiology, Anxiety physiopathology, Depression diagnosis, Depression epidemiology, Depression physiopathology, Dysbiosis, Gastrointestinal Diseases diagnosis, Gastrointestinal Diseases epidemiology, Gastrointestinal Diseases physiopathology, Gastrointestinal Microbiome, Humans, Immune System physiopathology, Prognosis, Risk Assessment, Risk Factors, Anxiety psychology, Brain physiopathology, Depression psychology, Gastrointestinal Diseases psychology, Gastrointestinal Tract innervation, Psychological Distress
- Abstract
Introduction: Psychological distress is associated with functional gastrointestinal disorders (FGIDs) including irritable bowel syndrome (IBS) and functional dyspepsia (FD) but only evidence from prospective longitudinal and treatment studies can indicate whether the link between FGIDs and psychological distress is causal. Emerging evidence suggests underlying biological mechanisms may explain the association of psychological distress with FGIDs., Areas Covered: This review critically evaluates whether anxiety and/or depression and FGIDs are causally related including evidence for a temporal sequence, strength and specificity of the association, biological gradient, and biological plausibility., Expert Opinion: Accumulating evidence suggests that psychological factors are causal for symptoms in a subset of FGID patients and not explained by health care seeking behavior (brain-gut disorder). In other cases, psychological factors may arise secondary to intestinal disease (gut-brain disorder). Prospective population-based studies are needed in FGIDs other than IBS and FD to determine if a similar brain-gut and gut-brain syndrome exists. Treatment studies have not phenotyped FGIDs according to brain-gut versus gut-brain origins which may be important in understanding true treatment efficacy. Future research needs to unravel biological mechanisms that may explain the link between psychological factors and FGIDs but promising data in the area of the brain-gut-immune-microbe axis is emerging.
- Published
- 2020
- Full Text
- View/download PDF
50. Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease.
- Author
-
Shah A, Talley NJ, Koloski N, Macdonald GA, Kendall BJ, Shanahan ER, Walker MM, Keely S, Jones MP, Morrison M, and Holtmann GJ
- Subjects
- Adult, Aged, Bacteria genetics, Bacteria isolation & purification, Bacterial Load, Biopsy, Breath Tests methods, Female, Gastrointestinal Diseases metabolism, Glucose metabolism, Humans, Inflammatory Bowel Diseases metabolism, Male, Middle Aged, Polymerase Chain Reaction methods, RNA, Ribosomal, 16S genetics, Duodenum microbiology, Gastrointestinal Diseases microbiology, Inflammatory Bowel Diseases microbiology
- Abstract
Background: Small intestinal bacterial overgrowth may play a role in gastrointestinal and non-gastrointestinal diseases., Aims: To use quantitative polymerase chain reaction (qPCR) to determine and compare bacterial loads of duodenal biopsies in asymptomatic controls, and patients with functional gastrointestinal disorders (FGIDs) and inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease (CD). To define effects of gastric acid inhibition on bacterial load, explore links of bacterial load and gastrointestinal symptoms in response to a standardised nutrient challenge and compare bacterial load with glucose breath test results., Methods: In 237 patients (63 controls, 84 FGID and 90 IBD), we collected mucosal samples under aseptic conditions during endoscopy extracted and total DNA. Bacterial load metric was calculated utilising qPCR measurements of the bacterial 16S rRNA gene, normalised to human beta-actin expression. Standard glucose breath test and nutrient challenge test were performed., Results: The duodenal microbial load was higher in patients with FGID (0.22 ± 0.03) than controls (0.07 ± 0.05; P = 0.007) and patients with UC (0.01 ± 0.05) or CD (0.02 ± 0.09), (P = 0.0001). While patients treated with proton pump inhibitors (PPI) had significantly higher bacterial loads than non-users (P < 0.05), this did not explain differences between patient groups and controls. Bacterial load was significantly (r = 0.21, P < 0.016) associated with the symptom response to standardised nutrient challenge test. Methane, but not hydrogen values on glucose breath test were associated with bacterial load measured utilising qPCR., Conclusions: Utilising qPCR, a diagnosis of FGID and treatment with PPI were independently associated with increased bacterial loads. Increased bacterial loads are associated with an augmented symptom response to a standardised nutrient challenge., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.